The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.

about

No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies.Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.Cytotoxic doses of ketoconazole affect expression of a subset of hepatic genes.

P2860

Q38894543-C35AE8C2-808B-45B0-82DC-FB4BC5CD10DC Q46132298-BA75E2C3-0844-4EE8-B0C2-2DF193D21103 Q46926951-F33CC4EF-793E-4D6C-A9D3-BFC5FAE14E6D

P2860

The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.

Item

http://www.wikidata.org/entity/Q46497132

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@en

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@nl

type

Item

label

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@en

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@nl

prefLabel

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@en

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@nl

P1476

The effect of ketoconazole on ...... ha 1A-adrenoceptor antagonist.

@en

P2093

A David Rodrigues

http://www.w3.org/2001/XMLSchema#string

Goutam C Mistry

http://www.w3.org/2001/XMLSchema#string

Gregory A Winchell

http://www.w3.org/2001/XMLSchema#string

John A Wagner

http://www.w3.org/2001/XMLSchema#string

Jutta L Miller

http://www.w3.org/2001/XMLSchema#string

Keith M Gottesdiener

http://www.w3.org/2001/XMLSchema#string

Prasad P Kari

http://www.w3.org/2001/XMLSchema#string

Richard C Simpson

http://www.w3.org/2001/XMLSchema#string

Thomas Marbury

http://www.w3.org/2001/XMLSchema#string

P2860

Tamsulosin for the treatment of benign prostatic hypertrophy

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety.

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

P304

699-703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270005275289

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15901753

http://www.w3.org/2001/XMLSchema#string

The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.

about

P2860

P2860

The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698